At one point in merger negotiations with Novartis, Avidity CEO Sarah Boyce and her team walked, cutting off access to a data ...
The FDA approved an intrathecal form of Novartis’ spinal muscular atrophy gene therapy Zolgensma on Monday, broadening access ...
Tecvayli plus Darzalex led to an 83% boost to progression-free survival versus the current standard therapy in relapsed or ...
Alicia Jackson formerly served as deputy director of the Biological Technologies Office at the Defense Advanced Research ...
Previous mega blockbusters took years to reach their peak sales. Lilly’s tirzepatide franchise is on course to exceed them ...
Richard Pazdur, the new director of the Center for Drug Evaluation and Research, raised concerns amid the rollout of several ...
Experts suggest the FDA’s Advanced Manufacturing Technologies designation could be a lifeline for improving production ...
Novo Nordisk’s amycretin showed no weight-loss plateau over 36 weeks in patients with type 2 diabetes, suggesting its efficacy could become even stronger with longer follow-up, according to analysts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback